$AQST

Aquestive Therapeutics, Inc.

Aquestive is a pharmaceutical company developing medicines and delivery technologies, including alternatives to invasive or inconvenient standard treatments. Its PharmFilm oral film technology delivers medicines buccally, sublingually or on the tongue. Aquestive is developing Anaphylm, a sublingual epinephrine prodrug film for severe allergic reactions, and AQST-108, a topical epinephrine prodrug gel. Its licensed portfolio includes products such as Suboxone, Sympazan, Libervant and Ondif, marketed by licensees in the United States and other countries. Aquestive manufactures licensed products and earns money through manufacturing and supply, licensing intellectual property, and related royalties, milestones and payments. The company also works with pharmaceutical companies to develop and commercialize medicines using its technologies. Its corporate headquarters and primary research laboratory facilities are in Warren, New Jersey, and its production facilities are in Portage, Indiana.

AlphAI earnings readthird quarter 2026 · NOV 3Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

1
2
0
$99K
$26K
Daly Richard J
33%
See all $AQST insider activity →
Med

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

Aquestive Therapeutics Highlights Anaphylm Review, Launch Plans and $90.3M Cash Position

Aquestive Therapeutics reported FDA acceptance of Anaphylm's NDA resubmission with a March 2027 PDUFA goal date. The company plans regulatory filings in Canada and the EU by 2027. As of September 2026, cash reserves were $90.3 million, with up to $95 million in additional funding possible. A U.S. launch with 65-80 sales reps is planned if approved.

Aquestive Therapeutics, Inc. (AQST): Jefferies Global Healthcare Conference November 16, 2026

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Regulation FD Disclosure. Jefferies Global Healthcare Conference November 16, 2026 © 2026 Aquestive Therapeutics, Inc. Disclaimer 2 This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive,” the “Company,” “we,” “our” or “us”) and contain “forwa

AQST sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning AQST (Aquestive Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.

Recent AQST coverage spans earnings, financial news and regulation.

In the last 30 days, AQST insiders filed 3 SEC Form 4 transactions — 2 purchases ($99K) and 1 sale ($26K). The most active reporter was Daly Richard J with 2 filings. 33% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving AQST

AlphAI scores every news story that mentions AQST with an AI model for sentiment and relevance, and aggregates insider trades from Aquestive Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AQST

Score

Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision

Aquestive Therapeutics (AQST) presented data on Anaphylm, a needle-free allergy treatment, showing faster absorption and higher blood pressure changes than EpiPen. The company expects FDA decision by 2027 and projects a $2B U.S. market by 2029. AQST plans to launch in Canada, Europe, and the U.K. in 2024. The company also discussed its sales strategy and pipeline, including Libervant and AQST-108.

Aquestive Therapeutics, Inc. (AQST): Jefferies Global Healthcare Conference November 16, 2026

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Regulation FD Disclosure. Jefferies Global Healthcare Conference November 16, 2026 © 2026 Aquestive Therapeutics, Inc. Disclaimer 2 This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive,” the “Company,” “we,” “our” or “us”) and contain “forwa

Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks

Aquestive Therapeutics (AQST) reported Q3 2026 revenue of $7.6M, down from $12.8M in Q3 2025, with a net loss of $16.5M. The company resubmitted its Anifilm NDA, with an FDA action date of March 16, 2027, and received a $10M upfront payment for out-licensing Libervant. AQST expects to end 2026 with over $70M in cash and is preparing for Anifilm's U.S. launch, hiring 75 sales reps. The FDA review timeline and pricing strategy remain uncertain.

Aquestive Therapeutics, Inc. (AQST): Corporate Presentation November 2026

Aquestive Therapeutics, Inc. (AQST) filed an SEC Form 8-K — Regulation FD Disclosure. Corporate Presentation November 2026 Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive,” the “Company,” “we,” “our” or “us”) and contain “forward-looking statements” within the meaning of the Private S

Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary

Aquestive Therapeutics reported Q3 2026 earnings, highlighting milestones like the NDA resubmission for Annamil and out-licensing of Libervant. Revenue grew 14% year-to-date due to increased license and royalty income. The company plans a spring 2027 launch for Annamil, with $95M in contingent funding available. Management expects to end 2026 with over $70M in cash. The Libervant deal provided a $10M upfront payment, with potential for $47.5M in milestones.

Aquestive (AQST) Q3 2026 Earnings Call Transcript

Aquestive (AQST) reported Q3 2026 earnings, highlighting progress on key milestones. The company resubmitted its ANNAFILM application, outlicensed Libervant, and refinanced debt. It expects over $70M in cash by year-end. ANNAFILM's FDA review is ongoing with a decision expected by March 16, 2027. The company is preparing for a potential US launch and expanding into Canada and Europe. AQST also discussed its pipeline and financial discipline.

What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call

Aquestive Therapeutics reported Q3 revenue of $7.6M, down from $12.8M YoY, due to Suboxone order fluctuations. The company discussed payer negotiations for Anaphylm, a potential differentiator in epinephrine treatment. Aquestive also announced a licensing deal for Libervant with Eton Pharmaceuticals, receiving a $10M upfront payment. The company expects to end 2026 with over $70M in cash and maintained its 2026 revenue outlook of $46M-$50M.

Related tickers